Search clinical trials for: RAS Wild type Metastatic Colorectal Cancer

Total 181428 results

Revolution Medicines, Inc.

Recruiting

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Colorectal Cancer | Pancreatic Ductal Adenocarcinoma | Gastrointestinal Cancer | CRC | Metastatic Pancreatic Ductal Adenocarcinoma | PDAC

United States
Wangxia LV

Recruiting

Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC

Colorectal Cancer Metastatic

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer

Metastatic Colorectal Cancer

China
City Clinical Oncology Hospital No 1
Atlas Biomed; N.N. Blokhin National Medical Research Center of Oncology; Moscow...

Recruiting

Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer (CRC01)

Colorectal Neoplasms | Chemotherapy Effect | Molecular Sequence Variation

Russian Federation
Roswell Park Cancer Institute

Recruiting

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Colo-rectal Cancer

United States
Sun Yat-sen University

Recruiting

Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer (CEIL)

Metastatic Colorectal Cancer

China
Australasian Gastro-Intestinal Trials Group
Olivia Newton-John Cancer Research Institute

Recruiting

Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Australia
University of Rome Tor Vergata

Recruiting

REVERT - taRgeted thErapy for adVanced colorEctal canceR paTients (REVERT)

Metastatic Colon Cancer

Italy, Spain, Romania
National University Hospital, Singapore

Recruiting

Role of Circulating Tumour DNA Testing in Assessing for Alterations of Primary Anti-EGFR Resistance in RAS/RAF Wild-type Metastatic Colorectal Cancer Patients

Colorectal Cancer

Singapore
West China Hospital
First Affiliated Hospital of Chongqing Medical University

Recruiting

First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes (CAPCET)

Colo-rectal Cancer | Capecitabine | Cetuximab

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Sichuan Kelun Pharmaceutical Research Institute...

Recruiting

Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC

Metastatic Colorectal Cancer

China
GCS IHFB Cognacq-Jay

Recruiting

Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases. (CETIDYL)

Cancer Colorectal

France
Cinnagen

Recruiting

Comparing Efficacy and Safety of Cetuximab (CinnaGen) Versus Erbitux® (Merck) in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Iran, Islamic Republic of
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC... and other conditions

United States
iOMEDICO AG
Amgen

Completed

Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE) (VALIDATE)

Metastatic Colorectal Cancer | RAS Wild-type

Germany
Taizhou Mabtech Pharmaceutical Co.,Ltd

Active, not recruiting

CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

China
Memorial Sloan Kettering Cancer Center
Amgen

Active, not recruiting

Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer

Metastatic Colorectal Cancer

United States
GERCOR - Multidisciplinary Oncology Cooperative...
Hoffmann-La Roche

Active, not recruiting

Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer (STRATEGIC-1)

Colorectal Cancer Metastatic

Ireland, France, Israel
University of Campania "Luigi Vanvitelli"

Completed

Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial (VELO)

Metastatic Colon Cancer

Italy
Spanish Cooperative Group for the Treatment of...
Amgen

Active, not recruiting

Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer (CR-SEQUENCE)

Colorectal Cancer

Spain
Taiho Oncology, Inc.
Institut de Recherches Internationales Servier

Completed

Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients (SUNLIGHT)

Refractory Metastatic Colorectal Cancer

United States, Poland, France, Germany, Hungary, Italy, Russian Federation, Ukraine, Austria, Belgium, Brazil, Denmark, Puerto Rico, Spain
Centre Leon Berard
Novartis

Completed

Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type (TRAHD)

Colorectal Cancer | Metastatic Cancer | Advanced Cancer

France
UNICANCER

Active, not recruiting

Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients (PANIRINOX)

Metastatic Colorectal Cancer

France
Federation Francophone de Cancerologie Digestive
Amgen

Active, not recruiting

FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation (OPTIPRIME)

Metastatic Colorectal Cancer

France, Martinique
NCIC Clinical Trials Group

Completed

Cetuximab With or Without Brivanib in Treating Patients With K-Ras Wild Type Tumours and Metastatic Colorectal Cancer

Colorectal Cancer

Canada
Canadian Cancer Trials Group
Pfizer

Completed

P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer.

Metastatic Colorectal Cancer

Canada
Criterium, Inc.
Amgen

Active, not recruiting

FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer

Colorectal Cancer Metastatic

United States
Emory University
National Cancer Institute (NCI); GlaxoSmithKline; National Institutes of Health...

Active, not recruiting

Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer (NIPAVect)

Microsatellite Stable | Stage IV Colorectal Cancer AJCC v8 | RAS Wild Type | MSI-H Colorectal Cancer | Metastatic Microsatellite Stable Colorectal Carcinoma | Advanced Microsatellite Stable Colorectal Carcinoma

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); Calithera Biosciences, Inc

Active, not recruiting

Novel PET/CT Imaging Biomarkers of CB-839 in Combination With Panitumumab and Irinotecan in Patients With Metastatic and Refractory RAS Wildtype Colorectal Cancer

Metastatic Colorectal Cancer | Colorectal Cancer | RAS Wild Type Colorectal Cancer | Refractory Colorectal Cancer

United States
Yuhong Li

Completed

Re-challenge of Anti-EGFR for Patients With RAS/BRAF Wild-type Metastatic CRC

Metastatic Colorectal Cancer

China
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)

Colorectal Neoplasms

Spain, United States, France, Italy, Belgium, Czechia, United Kingdom, Russian Federation
Amgen

Completed

Observational Study of Vectibix With Chemotherapy for Metastatic Colorectal Cancer Patients

Wild-type RAS Metastatic Colorectal Cancer
University of Campania "Luigi Vanvitelli"

Completed

Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal Cancer

Metastatic Colorectal Cancer | RAS Wild Type

Italy
National Cancer Institute, Naples

Completed

Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer (IMPROVE)

Colorectal Cancer Stage IV

Italy
NSABP Foundation Inc
Puma Biotechnology, Inc.

Active, not recruiting

Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

Metastatic Colorectal Cancer

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type

United States
Grupo Espanol Multidisciplinario del Cancer Digestivo
Amgen; Pivotal S.L.

Active, not recruiting

Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal (BEYOND)

Colorectal Cancer Metastatic

Spain
Grupo Espanol Multidisciplinario del Cancer Digestivo
Amgen; Pivotal S.L.

Completed

FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status (OPALO)

Neoplasm Metastasis | Colorectal Neoplasms | Colorectal Cancer Metastatic | Colorectal Carcinoma

Spain
Pfizer

Completed

Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors

Metastatic Colorectal Cancer

Belgium, Canada, France, Spain, United States, Italy, Netherlands
Amgen

Completed

ObservationaL Study on the Qol of RAS Wild-type mCRC Patients Receiving Anti-EGFR MAbs + FOLFOX or FOLFIRI as 1st Line (SILQ)

Metastatic Colorectal Cancer

Italy
University of Southern California
National Cancer Institute (NCI); Amgen

Terminated

5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Colorectal Adenocarcinoma | RAS Wild Type | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...

United States
Institut Cancerologie de l'Ouest

Terminated

Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer (SKINUX)

Colorectal Cancer Metastatic | Skin Toxicity

France
Gruppo Italiano per lo studio dei Carcinomi dell...

Unknown

Folfiri/aflIbercept in Metastatic coloreCTal Cancer patIents With RAS Validated Wild typE Status (DISTINCTIVE)

Advanced Colorectal Cancer

Italy
Merck KGaA, Darmstadt, Germany

Completed

A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients (TAILOR)

Metastatic Colorectal Cancer

China
Amgen
ZeinCRO Hellas SA

Completed

Prospective Observational Study of 1st and 2nd Line Vectibix® Use in RAS-wt mCRC Pts to Evaluate Pattern of Use and ORR (VISION)

Metastatic Colorectal Cancer

Greece
Universitaire Ziekenhuizen KU Leuven
Merck KGaA, Darmstadt, Germany

Completed

Cetuximab Standard or Dose Escalation in First Line Colorectal Cancer (Everest2)

Colorectal Cancer

Spain, France, Belgium, Hungary, Austria
Spanish Cooperative Group for the Treatment of...
Roche Pharma AG

Completed

Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC) (VISNU-2)

Colorectal Cancer Metastatic

Spain
Austrian Breast & Colorectal Cancer Study Group
Merck Gesellschaft mbH, Austria

Terminated

A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis (G-LUCAS)

Colorectal Cancer | Steatohepatitis

Austria
City of Hope Medical Center
National Cancer Institute (NCI)

Terminated

FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer

Recurrent Colorectal Carcinoma | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer

United States

Search clinical trials for: RAS Wild type Metastatic Colorectal Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations